ClinicalTrials.gg
Not yet recruitingNCT06341790Updated May 7, 2024

Effect of Consumption of Millet Diet in Patients With NAFLD

An interventional study of jowar based products in NAFLD, sponsored by Institute of Liver and Biliary Sciences, India. Not yet recruiting at 1 site in India. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-05-07.

Sponsored by Institute of Liver and Biliary Sciences, India · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Non-alcoholic Fatty Liver Disease by Institute of Liver and Biliary Sciences, India — 2 open to participants now, 2 under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Institute of Liver and Biliary Sciences, India.

Planned enrollment
6th of 10
60 · median 66
Started
2024
with 1 other
No phase
9 of 12
2 open now
Registered
11th of 12
by date

Among the 12 studies in Non-alcoholic Fatty Liver Disease by Institute of Liver and Biliary Sciences, India, this one is the 6th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2024, is one of 9 with no phase, and was the 11th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

2 of the 12 studies in Non-alcoholic Fatty Liver Disease by Institute of Liver and Biliary Sciences, India are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Non-alcoholic Fatty Liver Disease by Institute of Liver and Biliary Sciences, India, or all of them as a file.
02

Study summary

With NAFLD fast rising its ranks in becoming a major non communicable disease in India and across the globe, this study aims at primary prevention of the condition. NAFLD is a spectrum of diseases characterised by the deposition of fat within hepatocytes and is a precursor of liver inflammation. Global estimates peg the prevalence to be around 30 to 40%, but there are not many studies which have documented the prevalence in India. With the epidemiological transition, the cases of NAFLD are also on a rise as metabolic syndrome is an important risk factor.

It is apparent that the westernized way of our lifestyle especially the junk food culture comprising of super portions of loads of calories, sugars and salts is the main driver of this nutritional pandemic. The traditional diets in India were rich in fruits and vegetables, low in simple carbohydrates and high in fibre. Cereals are the main source of calories in any diet, forming the base of the food pyramid. Managing our cereals from being refined to the more complex ones being rich in fibre, protein and good quality fat could be a major player in the whole game of dietary modifications not just therapeutically but also prophylactically. Hence our therapeutic focus should be in increasing the consumption of cereals that are not only high in fibre, low in carbohydrates but also that have the potential to modulate the intestinal bacterial ecology to a more favourable type thus helping in intensifying the effects of overall dietary modifications.

Gut microbiota is currently explored for its role in NAFLD and there are gaps in knowledge which preclude having therapeutic strategies through its modulation. Millets, which were once considered to be poor man's diet are now becoming a part of the plate more frequently, especially for its unique nutritive content, with increased fiber, low carbohydrates, high protein and good quality fats. The processing methods may alter glycemic responses. Thus, the present study is proposed to look into the effect of millet based diets in reduction of hepatic steatosis and the resultant alterations in the gut microbiota .

Read the detailed description

a) Aim and Objective - Primary Objectives

  • To study the effect of millets based diet on hepatic steatosis in patients with NAFLD

Secondary Objective:

  • To study the effect of millets based diet on metabolic features like blood sugar levels, HbA1C, Insulin resistance, Lipid profile, and liver transaminases in patients with NAFLD.
  • To study the effect of millets based diet on body composition in patients with NAFLD
  • To study the effect of millets based diet on the profile of gut microbiota in patients with NAFLD (b) Methodology:

    • Study population: Out patients of departments of Hepatology and Clinical Nutrition, Institute of Liver and Biliary Sciences, New Delhi.
    • Study design: Randomized Controlled Trial - an open label study
    • Study Protocol: Newly diagnosed patients with non-alcoholic fatty liver (NAFL) attending the outpatient departments of Hepatology and Clinical Nutrition would be screened for eligibility for randomization into the study as per the inclusion and exclusion criteria. Thereafter the eligible patients would be randomized into the two groups - the control group (standard diet group) and the intervention group (Millets based diet group). All the patients would undergo a detailed clinical evaluation. Information would be collected regarding the onset and duration of symptoms, etiology, and severity of disease, other baseline clinical features, routine biochemical and hematological investigations, nutritional assessment. All the patients would be followed up at regular intervals in the OPD. Repeat assessment of all the parameters would be done at the end of intervention period of three months also.
    • Study Duration: 2 yrs
    • Follow up period: 3 months
    • Inclusion Criteria:
    • Recently diagnosed consenting adults with NAFL (steatotosis) of any grade with or without features of metabolic syndrome, diagnosed on the basis of ultrasound and /or liver transient eleastography (controlled attenuation parameter; CAP >250).
    • Age 18-60 years
    • Exclusion Criteria:
    • Pregnant \& lactating women
    • Age \<18 and >60 years
    • Individuals who had been hospitalised with complications of Diabetes mellitus, Chronic Kidney disease, Hypertension in the previous 6 months
    • Those with intake of antibiotics within last month
    • Seriously ill and bed ridden patients
    • Patients with viral hepatitis
    • Patients with significant alcohol consumption (regular consumption of > 10g per day for females and > 20g/d in males),
    • Patients having chronic inflammatory bowel disease or any chronic and autoimmune diseases will be excluded
    • Patients with NAFLD with associated hypertriglyceridemia that requires administration of statins.
    • Sample size with justification:
    • As there is no literature available on the direct effect of Millets based diet on NAFLD, hence the present study would be a proof of concept study. The total sample size planned is 60 patients with NAFLD i.e. 30 patients each in the control and intervention group.
    • Intervention: Nutritional Intervention with Millets including Ragi Flakes; Pearl Millet Flakes; Multi Millet Roti; Foxtail Millet Rice.
    • Intervention Groups:Control Group A (Standard Diet Group): This group would receive standard nutritional counselling with customized diet providing 20-25 Kcal/Kg and 1.0 gm protein/kg ideal body wt/day. 15-20% of the total calories as proteins, 50-60% of carbohydrates (Main Source: Wheat, Rice, Oats) and 25-30% of fats. Diet would be planned keeping in mind the individual food habits and choices. This group would not receive any nutritional supplement other than the prescribed diet.
    • Intervention Group B (Millets Diet Group): This group would receive standard nutritional counselling, customized diet providing 20-25 Kcal/Kg and 1.0 gm protein/kg ideal body wt/day. 15-20% of the total calories as proteins, 50-60% of carbohydrates (Main Source: Pearl millet flakes/Foxtail millet rice/multi millet roti) and 20-25% of fats. Diet would be planned keeping in mind the individual food habits and choices. This group would not receive any nutritional supplement other than the prescribed diet.
    • Physical activity recommendations: Brisk walking on a treadmill (at a speed 5-6 Kmph for 45 minutes) OR 5000 steps per day by pedometer counting
    • Duration of Intervention: Diets would be given for a period of three months.
    • Stopping rule for intervention:
    • Temporary Stopping Rules during the Study

      1. Non-compliance
      2. Allergic response to millets intervention
      3. Voluntary withdrawal.
03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Recently diagnosed consenting adults with NAFL (steatotosis) of any grade with or without features of metabolic syndrome, diagnosed on the basis of ultrasound and /or liver transient eleastography (controlled attenuation parameter; CAP >250).
  • Age 18-60 years

Exclusion criteria

Exclusion Criteria:

    • Pregnant \& lactating women
  • Age \<18 and >60 years
  • Individuals who had been hospitalised with complications of Diabetes mellitus, Chronic Kidney disease, Hypertension in the previous 6 months
  • Those with intake of antibiotics within last month
  • Seriously ill and bed ridden patients
  • Patients with viral hepatitis
  • Patients with significant alcohol consumption (regular consumption of > 10g per day for females and > 20g/d in males),
  • Patients having chronic inflammatory bowel disease or any chronic and diseases will be excluded
  • Patients with NAFLD with associated hypertriglyceridemia that requires administration of statins.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • No intervention
    Group A-Normal diet

    patients are advised normal diet for NAFLD

  • Experimental
    Group b-Millet Diet

    Patients are given millets based diet (jowar)

    Other: jowar based products

Interventions

  • Otherjowar based products

    jowar based products like jowar flakes, jowar aata, jowar vermicelli is given to the intervention group

06

What researchers measure

Primary outcomes

  1. Assessment of hepatic steatosis in NAFLD patients

    Change in hepatic steatosis as assessed by fibroscan, ultrasound (change in the CAP, LSM)

    Time frame: 3months

Secondary outcomes

  1. Assessment of blood sugar

    Change in blood sugar as assessed by blood fasting glucose, serum insulin \& HbA1c

    Time frame: 3months

  2. Assessment of lipid function

    Change in lipid parameters as assessed by blood lipid profile test

    Time frame: 3 months

  3. Assessment of liver transaminases

    Change in liver enzymes as assessed by liver function tests

    Time frame: 3 months

  4. Assessment of body composition

    Change in Nutritional status will be assessed using bioelectrical impedence analysis

    Time frame: 3 months

  5. Assessment of Gut Microbiota

    Change in gut microbiota will be assessed using 16S dNA extraction

    Time frame: 3months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2024; primary completion for Jul 2026, 25 months later.

Of 356 non-industry interventional studies with no phase under Non-alcoholic Fatty Liver Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's planned 25 months is close to that.

Counting every sponsor, half of 384 studies reached it within 25 months; a quarter within 12 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2024
First posted
Apr 2, 2024
StartEst.
May 15, 2024
Primary completionEst.
Jul 5, 2026
CompletionEst.
Jul 5, 2026
Last update
May 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06341790
Responsible party
Sponsor
First posted
Apr 2, 2024
Start date
May 15, 2024 (estimated)
Primary completion
Jul 5, 2026 (estimated)
Completion
Jul 5, 2026 (estimated)
Last update
May 7, 2024

Study contacts

Nida Athar, M.Sc
Contact
nidaathar.20@gmail.com
8601079163
Dr Jaya Joy Benajmin, Phd
principal investigator · Associate Professor, Clinical Nutrition at the Institute of Liver and Biliary Sciences (ILBS)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion